Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isconova has entered into an adjuvant license agreement with Crucell to use the company’s nano-particle Matrix M in two additional vaccine areas - HIV and malaria.
Subscribe to our email newsletter
Matrix M is an immune stimulating substance for use in vaccines, antibody production and immunological research.
Matrix M was already licensed to Crucell for use in influenza vaccines, under an existing agreement.
The results from a Phase I clinical trial with Isconova’s Matrix M adjuvant in an avian influenza vaccine showed increased number of antibody secreting cells and polyfunctional CD4+ Th1 cells.
The vaccine met all set criteria and was well tolerated without any serious adverse events.
Isconova CEO Lena Soderstrom said Isconova’s Matrix M induces both antibody-mediated and cellular immune responses, making it particularly suitable for vaccines in a number of disease areas.
"We consider it a confirmation of the strengths of our product that Crucell has selected Matrix M for use in two additional vaccine areas," Soderstrom said.